Fluticasone Furoate Evolan

What Is Fluticasone Furoate Evolan and What Is It Used For?

Fluticasone Furoate Evolan contains the active substance fluticasone furoate, a synthetic trifluorinated corticosteroid with potent anti-inflammatory properties. It belongs to the class of intranasal corticosteroids (INCSs), which are widely regarded as the most effective pharmacological treatment for allergic rhinitis according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines and the European Academy of Allergy and Clinical Immunology (EAACI).

The medication is indicated for the treatment of symptoms associated with both seasonal allergic rhinitis (commonly known as hay fever, triggered by pollen from trees, grasses, and weeds) and perennial allergic rhinitis (year-round symptoms caused by indoor allergens such as house dust mites, pet dander, and mould). Allergic rhinitis affects an estimated 10–30% of the global population according to the World Health Organization, making it one of the most common chronic conditions worldwide.

Fluticasone furoate works by binding with high affinity to the glucocorticoid receptor in the nasal mucosa. Once bound, it exerts its anti-inflammatory effects through multiple pathways: it inhibits the release of inflammatory mediators including prostaglandins, leukotrienes, and cytokines; reduces eosinophil infiltration and mast cell degranulation; and decreases vascular permeability in the nasal tissue. This comprehensive anti-inflammatory action addresses all four cardinal symptoms of allergic rhinitis — nasal congestion, rhinorrhoea (runny nose), sneezing, and nasal itching — as well as associated ocular symptoms such as watery, itchy eyes.

A key pharmacological advantage of fluticasone furoate is its extremely low systemic bioavailability of approximately 0.5% when administered intranasally. This means that the vast majority of the drug acts locally in the nasal passages with minimal absorption into the bloodstream, significantly reducing the risk of systemic corticosteroid side effects. The medication is primarily metabolized by the cytochrome P450 enzyme CYP3A4 in the liver and has a terminal elimination half-life of approximately 15 hours.

Clinical trials have demonstrated that fluticasone furoate nasal spray provides statistically significant improvements in total nasal symptom scores (TNSS) compared to placebo. In pivotal studies, patients experienced meaningful relief from nasal congestion, which is a symptom that many older antihistamines and some other intranasal corticosteroids address less effectively. The onset of action can be detected as early as 8 hours after the first dose, though maximum benefit is generally achieved after 3–4 days of regular daily use.

What Should You Know Before Using Fluticasone Furoate Evolan?

Contraindications

Fluticasone Furoate Evolan is contraindicated in patients with known hypersensitivity to fluticasone furoate or to any of the excipients contained in the formulation. Hypersensitivity reactions may include anaphylaxis, angioedema, rash, and urticaria. If you have previously experienced an allergic reaction to any corticosteroid nasal spray, inform your healthcare provider before starting treatment.

Warnings and Precautions

Several important precautions should be considered before and during the use of Fluticasone Furoate Evolan:

• Nasal conditions: If you have nasal ulcers, have recently undergone nasal surgery, or have experienced nasal trauma, you should delay using this medication until healing has occurred. The spray may impair wound healing in the nasal passages.
• Infections: Patients with untreated local or systemic fungal, bacterial, or viral infections should use intranasal corticosteroids with caution. Active pulmonary tuberculosis requires careful medical supervision.
• Adrenal suppression: Although systemic absorption is minimal, prolonged use at high doses may potentially cause hypothalamic-pituitary-adrenal (HPA) axis suppression. This risk is increased when intranasal corticosteroids are used in combination with other corticosteroid formulations (inhaled, oral, topical, or injectable). Symptoms of adrenal insufficiency may include fatigue, weakness, nausea, and hypotension.
• Growth in children: Prolonged use of intranasal corticosteroids may affect growth velocity in pediatric patients. Regular monitoring of height is recommended for children receiving long-term treatment. If growth is slowed, the treatment should be reviewed with the aim of reducing the dose to the lowest effective level.
• Visual disturbances: Systemic and topical corticosteroid use has been associated with the development of glaucoma and posterior subcapsular cataracts. Report any changes in vision to your doctor promptly.
• Epistaxis: Nosebleeds may occur during treatment. If severe or persistent epistaxis develops, treatment should be reviewed.
• Hepatic impairment: Patients with severe liver disease may have increased systemic exposure to fluticasone furoate. Close monitoring for systemic corticosteroid effects is advised.

Pregnancy and Breastfeeding

There is limited clinical data regarding the use of fluticasone furoate nasal spray during pregnancy. Animal reproductive studies have demonstrated adverse effects at high systemic corticosteroid exposures, which are consistent with the known pharmacological effects of this drug class. However, the very low systemic bioavailability (approximately 0.5%) of intranasal fluticasone furoate means that fetal exposure is expected to be negligible at recommended therapeutic doses.

Despite the low systemic absorption, Fluticasone Furoate Evolan should only be used during pregnancy when the expected benefit to the mother justifies the potential risk to the fetus. The ARIA guidelines note that intranasal corticosteroids may be considered in pregnant women with moderate-to-severe allergic rhinitis when symptoms significantly impair quality of life, but treatment decisions should always involve a careful risk-benefit assessment with the prescribing physician.

It is not known whether fluticasone furoate is excreted in human breast milk. Given the minimal systemic absorption following intranasal administration, any amount reaching breast milk is expected to be extremely small. A decision should be made whether to discontinue breastfeeding or to discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother. Consult your healthcare provider for personalized guidance.

How Does Fluticasone Furoate Evolan Interact with Other Drugs?

Fluticasone furoate is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Although systemic bioavailability from intranasal administration is very low (approximately 0.5%), co-administration with drugs that strongly inhibit CYP3A4 can significantly increase plasma concentrations of fluticasone furoate. This increase in systemic exposure raises the risk of corticosteroid-related adverse effects.

Interaction studies have demonstrated that ritonavir, a potent CYP3A4 inhibitor used in HIV treatment, can increase the area under the curve (AUC) of intranasal fluticasone by several-fold. Similar effects are expected with other potent CYP3A4 inhibitors. The clinical consequences of elevated systemic fluticasone levels can include Cushing’s syndrome (characterized by weight gain, moon face, skin thinning, and metabolic disturbances) and subsequent adrenal suppression upon withdrawal.

Major Interactions

Minor Interactions

Patients should always inform their healthcare provider about all prescription and non-prescription medications, vitamins, and herbal supplements they are taking. This is particularly important for HIV medications, antifungal agents, and any other corticosteroid preparations. Even supplements such as grapefruit juice, which is a moderate CYP3A4 inhibitor, could theoretically affect fluticasone furoate metabolism, though this interaction is unlikely to be clinically relevant at the low systemic doses achieved via intranasal administration.

What Is the Correct Dosage of Fluticasone Furoate Evolan?

Fluticasone Furoate Evolan should be administered by the intranasal route only. The spray must be primed before first use by shaking the bottle well and then actuating the pump 6 times until a fine mist is produced. If the spray has not been used for more than 30 days, or if the cap has been left off for 5 days or more, it should be re-primed by shaking and actuating once until a fine mist appears.

Adults and Adolescents (12 Years and Older)

Children (6–11 Years)

Elderly Patients

Missed Dose

If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Consistent daily use is important for achieving and maintaining optimal symptom control. Setting a daily reminder or incorporating the spray into your morning routine can help ensure regular use.

Overdose

Due to the very low systemic bioavailability of fluticasone furoate when administered intranasally, overdose is unlikely to cause acute symptoms requiring treatment beyond observation. In clinical trials, single intranasal doses of up to 2,640 micrograms (24 times the recommended daily adult dose) were well tolerated with no systemic adverse effects. However, chronic administration of excessive doses could theoretically lead to signs and symptoms of hypercorticism, including adrenal suppression. There is no specific antidote for fluticasone furoate overdose. If accidental overdose occurs, the patient should be observed and supportive treatment should be administered as appropriate.

What Are the Side Effects of Fluticasone Furoate Evolan?

Like all medicines, Fluticasone Furoate Evolan can cause side effects, although not everyone experiences them. The safety profile of fluticasone furoate nasal spray has been well characterized in extensive clinical trials involving thousands of patients. Most reported side effects are local (affecting the nose and throat) and are generally mild to moderate in severity.

The frequency of side effects is classified according to the following convention: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), and rare (affects fewer than 1 in 1,000 people). Understanding these frequencies can help you make informed decisions about your treatment and know which symptoms warrant medical attention.

Nosebleeds are the most frequently reported side effect and typically become more common with prolonged use. In most cases, epistaxis is mild (small amounts of blood-tinged mucus or spots of blood on a tissue) and does not require stopping the medication. Proper spray technique — directing the nozzle away from the nasal septum — can help minimize this risk. If you experience severe or persistent nosebleeds, contact your healthcare provider.

Nasal septum perforation is a rare but potentially serious complication of intranasal corticosteroid use. It occurs when a hole develops in the cartilage wall separating the two nostrils. Symptoms may include crusting in the nose, a whistling sound during breathing, or a sensation of nasal obstruction. If you notice any of these symptoms, stop using the spray and seek medical attention immediately.

Systemic side effects are extremely rare with intranasal fluticasone furoate due to its very low systemic bioavailability. However, patients using multiple corticosteroid products simultaneously (for example, an intranasal spray combined with an inhaled corticosteroid for asthma and a topical corticosteroid for eczema) should be aware that the cumulative systemic corticosteroid exposure may be significant enough to cause adrenal suppression, osteoporosis, or other systemic effects over time.

How Should You Store Fluticasone Furoate Evolan?

Proper storage of Fluticasone Furoate Evolan is important to maintain the effectiveness and safety of the medication. The nasal spray should be stored at a temperature below 30°C (86°F) and must not be frozen, as freezing can damage the suspension and alter the spray mechanism. Keep the bottle in its original outer carton to protect it from light exposure.

After first opening the bottle, the nasal spray should be used within 2 months. After this period, any remaining suspension should be discarded even if the bottle is not empty, as sterility can no longer be guaranteed. Always check the expiry date printed on the carton and bottle label before use. Do not use the medicine if it has passed its expiry date.

Keep the spray away from direct heat sources such as radiators or direct sunlight. Store the medication out of the sight and reach of children. Do not dispose of the spray via household waste or down drains. Ask your pharmacist about proper disposal of medicines you no longer use, in accordance with local regulations. Responsible disposal helps to protect the environment.

Between uses, always replace the protective cap on the nasal spray to keep the nozzle clean and to prevent accidental actuation. If the nozzle becomes blocked, do not attempt to clear it with a sharp object such as a pin, as this can damage the spray mechanism. Instead, remove the nozzle, soak it in warm water, rinse, and allow it to dry before reattaching.

What Does Fluticasone Furoate Evolan Contain?

The active substance in Fluticasone Furoate Evolan is fluticasone furoate. Each actuation of the nasal spray delivers 27.5 micrograms of fluticasone furoate from the nasal actuator. Fluticasone furoate is a white powder that is practically insoluble in water, and in this formulation it is presented as a suspension in an aqueous medium.

The excipients (inactive ingredients) in the formulation serve important functions in maintaining the stability, preservative efficacy, and spray characteristics of the product:

• Glucose (dextrose): Acts as a tonicity agent to adjust the osmolality of the suspension.
• Microcrystalline cellulose and carboxymethylcellulose sodium: Function as suspending agents that help maintain the even distribution of the active ingredient throughout the liquid, ensuring consistent dosing with each spray actuation.
• Polysorbate 80: A surfactant that helps stabilize the suspension and ensures uniform spray characteristics.
• Benzalkonium chloride: A preservative that prevents microbial contamination of the multi-dose spray bottle. Note: benzalkonium chloride may rarely cause irritation of the nasal mucosa in sensitive individuals.
• Edetate disodium (EDTA): A chelating agent that enhances the preservative efficacy of benzalkonium chloride.
• Purified water: The vehicle in which all other ingredients are dispersed.
• Hydrochloric acid or sodium hydroxide: Used to adjust the pH of the formulation to the optimal range for nasal administration.

Patients with known glucose intolerance or sensitivity to benzalkonium chloride should inform their healthcare provider before using this medication. The amounts of glucose contained in each spray are negligible and are not expected to affect blood sugar levels, even in patients with diabetes mellitus.

References

1. Brozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines — 2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958. doi:10.1016/j.jaci.2017.03.050
2. European Medicines Agency (EMA). Fluticasone furoate nasal spray — Summary of Product Characteristics. EMA/CHMP. Accessed January 2026.
3. U.S. Food and Drug Administration (FDA). Fluticasone furoate nasal spray prescribing information. FDA Label. Accessed January 2026.
4. Meltzer EO, Lee J, Tripathy I, et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2009;103(6):535-542. doi:10.1016/S1081-1206(10)60271-3
5. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS 2020). Rhinology. 2020;58(Suppl S29):1-464. doi:10.4193/Rhin20.600
6. British National Formulary (BNF). Fluticasone furoate. National Institute for Health and Care Excellence (NICE). Accessed January 2026.
7. World Health Organization (WHO). Allergic rhinitis and sinusitis. WHO Model Formulary. Geneva: WHO; 2024.
8. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017). Clin Exp Allergy. 2017;47(7):856-889. doi:10.1111/cea.12953
9. Maspero JF, Rosenblut A, Finn A, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008;138(1):30-37. doi:10.1016/j.otohns.2007.11.003
10. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292-1300. doi:10.1111/j.1398-9995.2008.01750.x

Editorial Team

This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in clinical pharmacology, otorhinolaryngology, and allergy medicine. All medical content follows the GRADE evidence framework and adheres to international guidelines from WHO, EMA, FDA, ARIA, and EAACI.